Assessing the Operational Feasibility of Evolutionary Therapy in Metastatic Non-Small Cell Lung Cancer

Clicks: 7
ID: 337885
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #101 of 102 articles by views in journal of evolutionary biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Evolutionary cancer therapy (ECT) applies principles of evolutionary game theory to prolong the effectiveness of cancer treatment by curbing the development of treatment resistance. It was shown to increase time to progression while decreasing the cumulative drug dose. ECT individually tailors treatment schedules for patients based on their cancer dynamics and, thus, requires regular follow-up and precise measurements of the cancer burden. The current literature on ECT often overlooks clinical realities, such as rather long intervals between tests, possible appointment delays and measurement errors, in the development of the treatment protocols. In this study, we assess the feasibility of ECT for metastatic non-small cell lung cancer (NSCLC) under clinically realistic follow-up constraints. We create virtual patients with cancer dynamics described by the polymorphic Gompertzian model, based on data from the START-TKI clinical trial. We assess the effects of longer test intervals, measurement error and appointment delays on the expected time to progression under the evolutionary therapy protocols. We show that a higher containment level, although it increases time to progression in the model's predictions, may lead to premature treatment failure in the presence of measurement error and appointment delay. Further, the ECT protocol with a single containment bound is demonstrated to be more robust to imprecise tumor burden measurements and delayed appointments than the protocol with two bounds. Finally, we show that a dynamically adjusted treatment protocol can be beneficial for individual patients, but requires a thorough follow-up. This study contributes to the design of a clinical trial and the future clinical implementation of evolutionary therapy for NSCLC.
Reference Key
openalex_W7131785596 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Arina Soboleva, Kailas Shankar Honasoge, Eva Molnárová, Ties A. Mulders, Anne‐Marie C. Dingemans, I Grossmann, Jafar Rezaei, Kateřina Staňková
Are you one of these authors? Claim your profile
Journal journal of evolutionary biology
Year 2026
DOI
10.1093/jeb/voag107
URL
https://academic.oup.com/jeb/advance-article-pdf/doi/10.1093/jeb/voag107/72616542/voag107.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.